Apyx Medical Corporation (NASDAQ:APYX) Stock Has Consensus Target Price of $6.60

Shares of Apyx Medical Corporation (NASDAQ:APYX) have been assigned a consensus rating of “Moderate Buy” from the eight research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $6.50.

APYX has been the subject of a number of recent research reports. Zacks Research raised Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, September 21st. Maxim Group assumed coverage on shares of Apyx Medical in a research report on Tuesday. They set a “buy” rating and a $6.00 price objective for the company. Finally, HC Wainwright started coverage on shares of Apyx Medical in a research report on Monday, July 13th. They set a “buy” rating and a $7.00 price objective for the company.

Institutional Trading of Apyx Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Nantahala Capital Management LLC purchased a new stake in shares of Apyx Medical during the 2nd quarter valued at approximately $14,683,414. AIGH Capital Management LLC purchased a new position in Apyx Medical in the second quarter worth approximately $5,066,000. Silverberg Bernstein Capital Management LLC increased its stake in Apyx Medical by 0.8% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 1,041,070 shares of the company’s stock worth $3,842,000 after acquiring an additional 8,067 shares during the last quarter. Sei Investments Co. increased its stake in Apyx Medical by 298.6% during the first quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock worth $2,208,000 after acquiring an additional 448,174 shares during the last quarter. Finally, BlackRock Inc. purchased a new stake in Apyx Medical in the second quarter valued at $2,519,000. Institutional investors and hedge funds own 55.33% of the company’s stock.

Apyx Medical Trading Up 2.0%

Shares of Apyx Medical stock opened at $2.50 on Friday. The company has a debt-to-equity ratio of 3.19, a current ratio of 5.68 and a quick ratio of 4.53. The stock’s 50 day simple moving average is $3.22 and its 200-day simple moving average is $3.73. The stock has a market cap of $105.30 million, a P/E ratio of -12.50 and a beta of 1.45. Apyx Medical has a 1-year low of $2.06 and a 1-year high of $5.08.

Apyx Medical (NASDAQ:APYX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. The firm had revenue of $13.88 million during the quarter, compared to analysts’ expectations of $13.18 million. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%. Analysts predict that Apyx Medical will post -0.25 EPS for the current fiscal year.

About Apyx Medical

Apyx Medical Corporation (NASDAQ: APYX) is a medical technology company that develops, manufactures and markets energy-based surgical products. The company focuses on systems that use its proprietary Helium Plasma technology to support tissue cutting, coagulation and soft-tissue procedures.

Apyx Medical’s product portfolio includes the Renuvion system, which is used in surgical and aesthetic procedures, and J-Plasma, an earlier generation of its Helium Plasma technology. Its products are marketed for use in fields such as plastic and cosmetic surgery, general surgery and other soft-tissue applications.

The company was formerly known as Bovie Medical Corporation and adopted the Apyx Medical name in 2018.